Improvement of the HAQ score by infliximab treatment in patients with RA: Its association with disease activity and joint destruction

Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Kouichi Amano, Tsutomu Takeuchi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We conducted a two-year prospective study to clarify the efficacy of infliximab at improving the health assessment questionnaire (HAQ) score and associated factors in 67 patients with advanced rheumatoid arthritis (RA). All patients were scheduled to receive infliximab at a dose of 3 mg/kg at weeks 0, 2, 6 and every eight weeks thereafter through to week 102, and were fully examined at the time of each infusion. Parameters of disease activity such as the serum level of C-reactive protein (CRP), the serum level of matrix metalloproteinase-3 (MMP-3) and the 28-joint disease activity score (DAS28) were obtained, and the functional capabilities of the patients were assessed using the HAQ score. The serum CRP, the MMP-3, the DAS28(CRP) level, and the mean HAQ score decreased rapidly at two weeks after the start of infliximab treatment (CRP from 3.7 to 0.9 mg/dl, MMP-3 from 362.3 to 192.8 ng/ml, DAS28(CRP) from 5.6 to 3.7, and HAQ score from 1.5 to 0.9). Compared with the baseline values, the mean progression of the modified van der Heijde (vdH) - Sharp score after one year was 4.4 ± 5.8 (median: 3.0), and that after two years was 3.1 ± 6.9 (median: 1.0). A 93% reduction in the rate of joint destruction, as measured using the vdH-Sharp score, was estimated after infliximab therapy. Patients with less joint damage (shorter disease duration or lower vdH-Sharp score) regained more of their daily activities. The present study demonstrated the importance of activity control before the progression of irreversible factors, such as joint destruction, for maintaining the functional capacities of RA patients.

Original languageEnglish
Pages (from-to)166-172
Number of pages7
JournalModern Rheumatology
Volume19
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Joint Diseases
C-Reactive Protein
Rheumatoid Arthritis
Matrix Metalloproteinase 3
Health
Joints
Therapeutics
Serum
Health Status
Blood Proteins
Surveys and Questionnaires
Infliximab
Prospective Studies

Keywords

  • 28-Joint disease activity score (DAS28)
  • Health assessment questionnaire (HAQ) score
  • Infliximab
  • Rheumatoid arthritis
  • Van der Heijde-Sharp score

ASJC Scopus subject areas

  • Rheumatology

Cite this

Improvement of the HAQ score by infliximab treatment in patients with RA : Its association with disease activity and joint destruction. / Nagasawa, Hayato; Kameda, Hideto; Sekiguchi, Naoya; Amano, Kouichi; Takeuchi, Tsutomu.

In: Modern Rheumatology, Vol. 19, No. 2, 2009, p. 166-172.

Research output: Contribution to journalArticle

Nagasawa, Hayato ; Kameda, Hideto ; Sekiguchi, Naoya ; Amano, Kouichi ; Takeuchi, Tsutomu. / Improvement of the HAQ score by infliximab treatment in patients with RA : Its association with disease activity and joint destruction. In: Modern Rheumatology. 2009 ; Vol. 19, No. 2. pp. 166-172.
@article{3327e14d4d7d4c79a9cc29fc70468a83,
title = "Improvement of the HAQ score by infliximab treatment in patients with RA: Its association with disease activity and joint destruction",
abstract = "We conducted a two-year prospective study to clarify the efficacy of infliximab at improving the health assessment questionnaire (HAQ) score and associated factors in 67 patients with advanced rheumatoid arthritis (RA). All patients were scheduled to receive infliximab at a dose of 3 mg/kg at weeks 0, 2, 6 and every eight weeks thereafter through to week 102, and were fully examined at the time of each infusion. Parameters of disease activity such as the serum level of C-reactive protein (CRP), the serum level of matrix metalloproteinase-3 (MMP-3) and the 28-joint disease activity score (DAS28) were obtained, and the functional capabilities of the patients were assessed using the HAQ score. The serum CRP, the MMP-3, the DAS28(CRP) level, and the mean HAQ score decreased rapidly at two weeks after the start of infliximab treatment (CRP from 3.7 to 0.9 mg/dl, MMP-3 from 362.3 to 192.8 ng/ml, DAS28(CRP) from 5.6 to 3.7, and HAQ score from 1.5 to 0.9). Compared with the baseline values, the mean progression of the modified van der Heijde (vdH) - Sharp score after one year was 4.4 ± 5.8 (median: 3.0), and that after two years was 3.1 ± 6.9 (median: 1.0). A 93{\%} reduction in the rate of joint destruction, as measured using the vdH-Sharp score, was estimated after infliximab therapy. Patients with less joint damage (shorter disease duration or lower vdH-Sharp score) regained more of their daily activities. The present study demonstrated the importance of activity control before the progression of irreversible factors, such as joint destruction, for maintaining the functional capacities of RA patients.",
keywords = "28-Joint disease activity score (DAS28), Health assessment questionnaire (HAQ) score, Infliximab, Rheumatoid arthritis, Van der Heijde-Sharp score",
author = "Hayato Nagasawa and Hideto Kameda and Naoya Sekiguchi and Kouichi Amano and Tsutomu Takeuchi",
year = "2009",
doi = "10.1007/s10165-008-0142-0",
language = "English",
volume = "19",
pages = "166--172",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Improvement of the HAQ score by infliximab treatment in patients with RA

T2 - Its association with disease activity and joint destruction

AU - Nagasawa, Hayato

AU - Kameda, Hideto

AU - Sekiguchi, Naoya

AU - Amano, Kouichi

AU - Takeuchi, Tsutomu

PY - 2009

Y1 - 2009

N2 - We conducted a two-year prospective study to clarify the efficacy of infliximab at improving the health assessment questionnaire (HAQ) score and associated factors in 67 patients with advanced rheumatoid arthritis (RA). All patients were scheduled to receive infliximab at a dose of 3 mg/kg at weeks 0, 2, 6 and every eight weeks thereafter through to week 102, and were fully examined at the time of each infusion. Parameters of disease activity such as the serum level of C-reactive protein (CRP), the serum level of matrix metalloproteinase-3 (MMP-3) and the 28-joint disease activity score (DAS28) were obtained, and the functional capabilities of the patients were assessed using the HAQ score. The serum CRP, the MMP-3, the DAS28(CRP) level, and the mean HAQ score decreased rapidly at two weeks after the start of infliximab treatment (CRP from 3.7 to 0.9 mg/dl, MMP-3 from 362.3 to 192.8 ng/ml, DAS28(CRP) from 5.6 to 3.7, and HAQ score from 1.5 to 0.9). Compared with the baseline values, the mean progression of the modified van der Heijde (vdH) - Sharp score after one year was 4.4 ± 5.8 (median: 3.0), and that after two years was 3.1 ± 6.9 (median: 1.0). A 93% reduction in the rate of joint destruction, as measured using the vdH-Sharp score, was estimated after infliximab therapy. Patients with less joint damage (shorter disease duration or lower vdH-Sharp score) regained more of their daily activities. The present study demonstrated the importance of activity control before the progression of irreversible factors, such as joint destruction, for maintaining the functional capacities of RA patients.

AB - We conducted a two-year prospective study to clarify the efficacy of infliximab at improving the health assessment questionnaire (HAQ) score and associated factors in 67 patients with advanced rheumatoid arthritis (RA). All patients were scheduled to receive infliximab at a dose of 3 mg/kg at weeks 0, 2, 6 and every eight weeks thereafter through to week 102, and were fully examined at the time of each infusion. Parameters of disease activity such as the serum level of C-reactive protein (CRP), the serum level of matrix metalloproteinase-3 (MMP-3) and the 28-joint disease activity score (DAS28) were obtained, and the functional capabilities of the patients were assessed using the HAQ score. The serum CRP, the MMP-3, the DAS28(CRP) level, and the mean HAQ score decreased rapidly at two weeks after the start of infliximab treatment (CRP from 3.7 to 0.9 mg/dl, MMP-3 from 362.3 to 192.8 ng/ml, DAS28(CRP) from 5.6 to 3.7, and HAQ score from 1.5 to 0.9). Compared with the baseline values, the mean progression of the modified van der Heijde (vdH) - Sharp score after one year was 4.4 ± 5.8 (median: 3.0), and that after two years was 3.1 ± 6.9 (median: 1.0). A 93% reduction in the rate of joint destruction, as measured using the vdH-Sharp score, was estimated after infliximab therapy. Patients with less joint damage (shorter disease duration or lower vdH-Sharp score) regained more of their daily activities. The present study demonstrated the importance of activity control before the progression of irreversible factors, such as joint destruction, for maintaining the functional capacities of RA patients.

KW - 28-Joint disease activity score (DAS28)

KW - Health assessment questionnaire (HAQ) score

KW - Infliximab

KW - Rheumatoid arthritis

KW - Van der Heijde-Sharp score

UR - http://www.scopus.com/inward/record.url?scp=64449085974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64449085974&partnerID=8YFLogxK

U2 - 10.1007/s10165-008-0142-0

DO - 10.1007/s10165-008-0142-0

M3 - Article

C2 - 19083077

AN - SCOPUS:64449085974

VL - 19

SP - 166

EP - 172

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 2

ER -